BNA035 / Fosun Pharma, Binacea Pharma - LARVOL DELTA

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Shanghai Henlius Biotech | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Binacea Pharma, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Glioblastoma • Oncology • Solid Tumor • CD4

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech

Combination therapy • New P1 trial • Oncology • Solid Tumor

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Recruiting | Sponsor: Shanghai Henlius Biotech | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Binacea Pharma, Inc.

Clinical • New P1 trial • Glioblastoma • Oncology • Solid Tumor • CD4 • MRI